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Abstract
Background: The aim of this study was to compare the outcome of 3 months vs. 18 months of 
amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the 
first episode of persistent AF.
Methods: We included 51 patients who experienced the first episode of persistent AF receiving 
amiodarone (600 mg) daily for 4–6 weeks. If AF persisted, electrical cardioversion (ECV) 
was performed. All patients received amiodarone (200 mg daily) for 3 months and then were 
randomized to amiodarone (Group I) or placebo (Group II) and followed for 15 months. The 
control group comprised 9 untreated patients undergoing ECV. Treatment effectiveness was 
evaluated using a Bayesian model.
Results: Eighteen months after AF reversion, 22 (81.5%) patients in Group I, 13 (54.2%) 
patients in Group II, and 1 (11.1%) patient in the control group remained in sinus rhythm. 
No differences were found between Group I patients who required ECV and Group II patients. 
Sinus rhythm was preserved in all Group I patients when it was achieved during amiodarone 
administration. Limiting adverse effects occurred in 3 (11.1%) patients in Group I.
Conclusions: In patients regaining sinus rhythm after the first episode of persistent AF,  
a 3-month amiodarone treatment after reversion is a reasonable option for rhythm control. 
(Cardiol J 2014; 21, 4: 397–404)
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Introduction
Atrial fibrillation (AF) is the most common 
sustained tachyarrhythmia found in the adult po-
pulation. It occurs in about 2–3% of the general 
population over 60 years of age, and in nearly 10% 
of individuals above 80 years. Long-term preven-
tion of arrhythmia relapses reduces morbidity and 
improves quality of life and exercise capacity [1, 2]. 
Therefore, restoration of normal sinus rhythm (SR) 
is usually attempted in patients with persistent AF, 
either by pharmacological or electrical means [3].
It is established that in the absence of an-
tiarrhythmic therapy, successful cardioversion of 
the first episode of persistent AF is followed by 
a high rate of relapses (> 75% at 1 year). This 
can be prevented in a substantial percentage of 
patients by using long-term amiodarone therapy 
[4–6]. However, amiodarone treatment is as-
sociated with significant side effects, including 
hyperthyroidism or hypothyroidism, pulmonary 
and hepatic toxicity, and neurological symptoms, 
which may preclude the benefits of this approach 
[7, 8]. These side effects are much more frequent 
after long-term treatments. We hypothesized that 
maintenance of SR with amiodarone after reversion 
of the first episode of persistent AF for a period 
of only 3 months, may attenuate, or even reverse, 
arrhythmia-induced atrial remodeling [9–11]. This, 
in turn, could prevent AF recurrences and elimi-
nate the need for long-term amiodarone therapy 
and the associated side effects. Thus, the aim of 
this study was to evaluate comparatively the rate 
of AF recurrences and amiodarone-related major 
adverse events during an 18-month follow-up pe-
riod. Amiodarone was administered to patients with 
first-episode persistent AF (lasting no longer than 
1 year after onset) for a period of only 3 months, 
or throughout the 18-month period.
Methods
Patient population and study protocol
Patients with persistent AF lasting more 
than 1 week and less than 1 year were included 
in this study. During the run-in period, persistent 
arrhythmia was documented with at least 3 resting 
electrocardiography (ECG) recordings, performed 
at different intervals, and by a 24-h ECG Holter 
monitor in the week prior to the initiation of the 
study. Exclusion criteria included: paroxysmal 
AF; atrial flutter; acute myocardial infarction in 
the preceding 6 months; PR interval > 0.28 s in 
ECGs recorded prior to AF onset; second or third 
degree atrioventricular block in ECG tracings ob-
tained before AF occurrence (unless a permanent 
pacemaker was implanted), spontaneous heart rate 
< 50 bpm; evidence of sinus node dysfunction with-
out implanted pacemaker; QTc interval ≥ 0.50 s; 
thyroid dysfunction; abnormal liver function tests; 
chronic lung disease; pregnancy; anteroposterior 
left atrium diameter ≥ 60 mm; severe mitral steno-
sis or insufficiency; severe tricuspid regurgitation; 
elevated pulmonary artery systolic pressure; con-
traindications for anticoagulation; co-morbidities 
conditioning short-term prognosis; inability to 
attend follow-up sessions for any reason; and 
denied consent. The first documented recurrence 
of AF was considered the end follow-up point for 
every patient.
All participants underwent a baseline cardio-
vascular evaluation that consisted of a complete 
clinical examination, ECG at rest, 24-h ECG Holter 
recording, chest radiography, 2-dimensional (2-D) 
echocardiogram with Doppler, and standard labo-
ratory tests, including thyroid hormone concen-
trations. All patients, effectively anticoagulated 
for at least 4 weeks (international normalization 
ratio: 2.0–3.0), were loaded with oral amiodarone 
(600 mg/daily) for 4–6 weeks. Patients who regai-
ned SR during this period were subsequently trea-
ted with amiodarone (200 mg/daily) for 3 months. In 
those individuals in whom AF persisted, electrical 
cardioversion (ECV) was performed under general 
anesthesia with an initial direct current monophasic 
shock of 200 joules and additional shocks of 360 jo - 
ules when the first shock was ineffective. After 
successful ECV, amiodarone was administered at 
daily doses of 200 mg for 3 months.
Patients were subsequently randomized in 
a double-blind fashion to receive amiodarone, 200 mg 
daily (Group I) or placebo (Group II). Both groups 
were followed for 15 months. A third group that 
did not receive any treatment (control group) and 
comprised 9 patients undergoing ECV without 
antiarrhythmic treatment before and after con-
version to SR. Follow-up evaluation consisted of 
a clinical examination and an ECG at rest every 
30 days. A more complete assessment, including 
chest X-ray, 24-h Holter ECG, 2-D echocardio-
gram with Doppler, and standard laboratory tests 
including thyroid function tests, was performed at 
6-month intervals, or at any time when cardiova-
scular or non-cardiovascular symptoms occurred. 
When appropriate, anticoagulation was interrupted 
after at least 1 month of permanent SR.
Seven centers in Argentina engaged in this 
trial complied with the principles of the Declaration 
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of Human Rights of Helsinki, and the study protocol 
was approved by the Ethical Board of each center. 
All patients were informed about the purpose of the 
study and they provided written informed consent 
before the enrollment.
Statistical analysis
The antiarrhythmic effect of amiodarone tre-
atment is expressed as Ø; Ø1 = pa − pp and 
Ø2 = pp − pc, where pa is the proportion of AF re-
currence in Group I, pp represents the proportion 
of recurrence in Group II, and pc is the proportion 
of AF recurrence in the control group.
The inference with regard to Ø was made by 
means of a Bayesian perspective on the estimation 
of the posterior probability density (ppd) of Ø. 
This was obtained for the whole group and for the 
subgroups defined by an interest factor (conditional 
group) and estimated by means of a Monte Carlo 
simulation assuming a previous non-informative 
distribution of both parameters. The information 
about Ø contained in ppd is resumed by the median 
and a 95% credibility interval of equiprobability at 
the extremes.
Results
Table 1 summarizes the baseline clinical cha-
racteristics of patients assigned to the 2 arms of 
the study. The 2 groups were well matched with re-
spect to baseline clinical findings. The predominant 
underlying disease was systemic hypertension, 
and most of the patients had evidence of structural 
heart disease. Group I included 27 patients, Group II 
24 patients, and the control group included 9 pa-
tients who underwent ECV without antiarrhythmic 
treatment before and after conversion to SR.
In total, out of 51 patients, 30 (58.8%), who 
received loading amiodarone treatment, regained 
normal SR during the initial 4–6 weeks of thera-
py, while in the remaining 21 patients, this was 
accomplished using ECV. SR was restored during 
the initial period of amiodarone administration in 
16 (59.26%) patients of Group I and in 14 (58.33%)
patients of Group II. Furthermore, 11 patients in 
Group I and 10 patients in Group II did require ECV, 
as shown in Figure 1.
Figure 2 depicts the Kaplan-Meier survival 
estimates of SR maintenance in the 3 study groups, 
while Figure 3 displays the Kaplan-Meier survival 
estimates of SR persistence during long-term and 
short-term amiodarone treatment, according to 
the AF reversion mode during the initial period of 
amiodarone therapy. After the 18-month follow-up 
period, normal SR was still present in 22 (81.5%) pa-
tients of Group I, in 13 (54.2%) patients of Group II, 
and in only 1 (11.1%) patient of the control group. 
The rate of SR maintenance at the end of the 
follow-up period was similar in patients receiving 
amiodarone for 3 months and those on long-term 
treatment (Group I) that had required ECV. All 
patients of Group I in whom AF was converted 
Table 1. Baseline clinical characteristics of the patients.
Amiodarone (n = 27) Placebo (n = 24) Total (n = 51)
Age (x) 50–83 (69.3) 50–80 (67.2) 50–83 (67.9)
Sex (male) 20 18 38
Dilated cardiomyopathy 4 5 9
Coronary heart disease 4 3 7
Hypertension 17 12 29
Lone AF 4 3 7
AF duration indeterminate 
(> 1 month)
1–12 month
(x = month)
4
23 (x = 4.0)
6
18 (x = 5.3)
10
41 (x = 4.6)
Echocardiography Amiodarone Placebo Total (n = 51)
LV diastolic diameter [mm] 34–62 (x = 50.9) 40–70 (x = 52.7) 34–70 (x = 51.7)
LV systolic diameter [mm] 19–52 (x = 33.2) 22–56 (x = 35.4) 19–56 (x = 34.3)
Interventricular septum [mm] 8–15 (x = 11.3) 7–16 (x = 11.3) 7–16 (x = 11.3)
Posterior wall [mm] 7–13 (x = 10.0) 7–14 (x = 10.2) 7–14 (x = 10.1)
Left atrium anteroposterior diameter [mm] 34–59 (x = 47.3) 35–63 (x = 46.6) 34–63 (x = 46.8)
AF — atrial fibrillation; LV — left ventricular
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pharmacologically during the initial 4–6 weeks of 
amiodarone therapy maintained normal SR at the 
end of follow-up. In marked contrast, in the same 
group, this occurred in only 54.5% of patients who 
required ECV. In Group II patients, long-term 
maintenance of normal SR was observed in 50% 
of patients who recovered SR pharmacologically 
during the initial 4–6 weeks of amiodarone treat-
ment and in 60% of those who underwent ECV. 
Significant adverse effects were seen in 3 (11.1%) 
patients receiving long-term amiodarone treatment 
(2 patients developed hyperthyroidism and 1 pa-
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Figure 1. Study protocol in patients with first episode of persistent atrial fibrillation; ECV — electrical cardioversion; 
PhCV — pharmacologic cardioversion; SR — sinus rhythm.
Figure 2. Kaplan-Meier survival estimates of sinus rhythm maintenance during long-term and after short-term amio-
darone (amio) therapy.
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tient had overt manifestations of hypothyroidism). 
None of the patients under short-term amiodarone 
therapy exhibited limiting side effects.
Figure 4 shows the smoothed curves of the 
probability density function of Ø (risk difference). 
In density amiodarone long-amiodarone short 
(DAL-AS) ECV, the Ø area is equiprobable to both 
sides of zero, which indicates no differences in 
the recurrence risk of arrhythmia. However, for 
DAL-AS pharmacological cardioversion (PhCV) 
as well as for DAS-control, the whole Ø area 
is virtually located to the left of 0, resulting in 
a clear risk reduction of AF recurrence. Moreover, 
for all groups in DAL-AS, the area Ø is to the left 
in an intermediate location, and indicates a risk 
reduction, though of lesser magnitude. The average 
means values are shown at the bottom of Figure 4.
Discussion
The clinical benefits of restoration and ma-
intenance of SR in patients with persistent AF, 
including improvements in quality of life and fun-
ctional capacity, as well as reduced morbidity and 
mortality, have been widely reported [1, 2, 12–16]. 
Diverse pharmacologic strategies directed toward 
long-term preservation of normal SR after rever-
sion of persistent AF have been proposed, with 
modest antiarrhythmic efficacy and the incidence 
of limiting and even harmful adverse effects [17, 
18]. Long-term amiodarone treatment is among the 
most effective treatments for promoting normal SR 
maintenance in patients with persistent AF [4–7]. 
However, the untoward side effects of the drug 
increase along with the duration of administration.
In this study, out of 51 patients, 35 (68.6%) 
with the first-episode of persistent AF who reco-
vered normal SR either by amiodarone alone, or by 
ECV, and did not experience arrhythmia relapses 
during the initial 3-month treatment period, rema-
ined in normal SR after 18 months of follow-up. 
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Figure 4. Curves disclosing the posterior probability 
density (PPD) of atrial fibrillation recurrence risk by me-
ans of a Bayesian perspective; DAL-AS ECV — density 
amiodarone long-amiodarone short electrical cardiover-
sion; DAL-AS — density amiodarone long-amiodarone 
short; PhCV — pharmacologic cardioversion; DAS-con-
trol — density amiodarone short-control.
Figure 3. Kaplan-Meier survival estimates of sinus rhythm persistence according to atrial fibrillation reversion mode; 
amio — amiodarone; ECV — electrical cardioversion; PhCV — pharmacologic cardioversion.
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This was in contrast with the poor outcome do-
cumented in 8 of 9 (88.9%) control patients, who 
developed AF relapses early in the follow-up pe-
riod. Likewise, it is clear that long-term treatment 
is more effective than short-term treatment in 
patients regaining SR during the first 4–6 weeks of 
therapy (100% vs. 50%). In a previous study, 45 of 
56 patients (83.6%) who experienced persistent 
AF and had their normal rhythm restored by oral 
amiodarone treatment, remained in SR at the 
18-month follow-up [7]. In the present study, all 
patients under this condition retained SR at the 
end of the follow-up period, likely due to the small 
sample size. Further, long-term administration 
provides a high rate of rhythm control, but limiting 
side effects are more frequent as observed in 3 out 
of 27 patients in Group I (11.1%) who developed 
clinically significant thyroid dysfunction and not 
seen in patients assigned to receive the placebo 
after the first 3 months of amiodarone treatment. 
Conversely, short-term amiodarone treatment is 
accompanied by a higher chance of AF relapses, 
but fewer or no serious side effects. The fact that 
amiodarone can be administered to patients even 
in the presence of structural heart disease and 
advanced heart failure is a significant additional 
advantage, given the contraindications of these 
conditions for other antiarrhythmic drugs.
No significant differences were found in outco-
mes for patients assigned to long-term and short-
-term amiodarone therapy, whose normal SR was 
restored by ECV, and those under short-term treat-
ment, and whose normal SR was restored following 
the initial period of amiodarone administration.
Little information is available on the results 
of short-term amiodarone administration after 
conversion of the first episode of persistent AF. 
Channer et al. [19] achieved pharmacological 
reversion of the arrhythmia in 21% (26/123) of pa-
tients, although this study differs from our study in 
several aspects, and the reported results are not 
too different from those described here. However, 
these investigators used a relatively low loading 
dose of amiodarone (400 mg/day for 2 weeks), and 
in addition, short-term amiodarone therapy (200 mg 
daily) lasted only 8 weeks, while long-term the-
rapy was prolonged to 52 weeks. A year later, 
20 out of 48 patients (42%) who received short-
-term amiodarone were in normal SR, while the 
same antiarrhythmic effect was documented in 
30 out of 48 patients (63%) under long-term tre-
atment. In marked contrast, normal SR persisted 
in only 2 out of 30 patients (6.66%) not receiving 
amiodarone (control group). Limiting adverse 
effects were observed in 8% and 18% of patients 
receiving short-term and long-term amiodarone, 
respectively, and in 3% in the control group.
Ahmed et al. [20] analyzed the rate of AF 
recurrences in patients who underwent transient 
(1 month) or continuous amiodarone treatment after 
reversion of recurrent episodes of persistent AF, 
and restarted amiodarone administration in the 
first group whenever AF relapsed. After a mean 
follow-up of 25 months, the percentage of patients 
maintaining normal SR was 48% in those transien-
tly treated with 200 mg of amiodarone, and 62% in 
patients under continuous therapy with the same 
doses. However, the rate of AF recurrences was 
notably higher (80%) in the transient group than 
in the continuous group (54%; p < 0.001). In this 
study, no significant differences were found in the 
incidence of adverse events that could be related 
to the duration of amiodarone treatment (19% vs. 
24%). Of note, mortality and hospitalization rates 
were significantly greater in patients with short-
-term amiodarone (53%) compared with those 
receiving continuous therapy (34%) (p = 0.002). 
The main implication of this study is that patients 
under amiodarone therapy for only 1 month after 
reversion of persistent AF show a higher incidence 
of arrhythmia recurrence, mortality, and cardio-
vascular hospitalizations. The main differences 
between the work of Ahmed et al. [20] and our 
study is that they included patients who had had 
AF relapses, the short-term treatment with amio-
darone lasted only for 1 month, and AF relapses 
were reverted during follow-up.
Influenced by the latest guidelines and con-
sensus, many cardiologists do not recommend 
systematic treatment with antiarrhythmic agents 
after the first episode of persistent AF, except in 
patients in whom the arrhythmia is accompanied 
by hemodynamic derangement or is highly sympto-
matic. In the absence of prophylactic treatment, the 
rate of relapses after AF conversion is high (more 
than 75% at 1 year after the initial crisis) [19]. This 
approach is partly supported by studies in which 
no significant difference was found in morbidity 
or mortality, with strategies directed to heart rate 
control or rhythm control [7, 21]. However, this is 
conflicted by additional studies which report that 
SR preservation is associated with a lower risk of 
mortality and stroke, and improvement of functio-
nal capacity and quality of life [12, 13, 22].
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Does maintenance of SR during 3-month 
treatment with amiodarone revert atrial 
remodeling?
Atrial remodeling in AF is induced by the ra-
pid atrial rate and results in electrophysiological 
and structural changes that favor initiation and 
maintenance of arrhythmia [23]. Based on this 
concept, any antiarrhythmic treatment that seeks 
to maintain SR may prevent or even reverse atrial 
remodeling, which is a crucial factor to avoid AF 
relapses after reversion of the arrhythmia [10, 
23]. Electrophysiological atrial remodeling is 
characterized by a shortening of repolarization, 
refractoriness dispersion, and slow impulse pro-
pagation. Abbreviation of atrial refractoriness is 
related to downregulation of L-type Ca2+ currents 
resulting from intracellular calcium overload due 
to the rapid atrial rate [23]. This change leads to 
shorter atrial wavelengths, favoring the occurrence 
of multiple wavelet re-entries and thus increasing 
the susceptibility to AF and likelihood of AF ma-
intenance [23, 24]. Additionally, increased atrial 
size may be important in this process since it 
may facilitate more re-entry circuits, and it is an 
important clinical predictor for AF development 
and perpetuation [25]. AF remodeling is not 
a permanent event, since even in persistent AF, the 
remodeling is reversible, a fact that is of paramount 
importance in the management of patients with 
this form of AF. Indeed, conversion of AF to SR, 
either by electrical or pharmacologic means or 
after radiofrequency ablation, reduces atrial size 
[25, 26], and improves atrial contractility [27−29].
Disappearance of structural and functional 
changes generally lags behind the reversal of 
electrical remodeling [29, 30]. However, although 
reversal of electrical remodeling can be rapidly 
achieved [28, 29], the chance of AF recurrence 
may also depend on the underlying structural ab-
normalities [25]. Abbreviation of the P-wave and 
prolongation of the atrial refractory period, accom-
panied with reduced susceptibility to AF are the 
primary manifestations of reverse electrophysio-
logical remodeling. These findings were reported 
only in AF patients who remain in SR and not in 
those who have AF recurrences. Furthermore, 
a high-resolution signal-averaged P-wave at 1 month 
and 3 months post cardioversion, has significantly 
decreased in those patients who remained in SR, 
whereas this has not been observed in those who 
relapsed [28]. It was postulated that the electrop-
hysiological effects of amiodarone by itself might 
help to reverse atrial remodeling. In fact, in an 
experimental study in dogs by Shinagawa et al. [10], 
the administration of amiodarone after induction 
of atrial tachycardia remodeling by rapid pacing, 
reversed remodeling within days, although that 
rapid atrial pacing persisted during amiodarone 
therapy.
Limitations of the study
Although the small number of patients studied 
is a limitation, the detailed statistical analysis 
described in Results validates the conclusions of 
our study. Notwithstanding this fact, further larger 
studies are needed to better assess the safety and 
efficacy of the approach proposed in this study.
The ECGs performed during regular check-
-ups throughout the follow-up period, and at the 
end of the study, do not completely rule out the 
possibility of asymptomatic paroxysmal AF epi-
sodes. However, in the AFFIRM protocol as well 
as in the RECORD AF [7, 18], the success of eva-
luating rhythm control was based on single ECG 
recordings.
Conclusions
The findings of the current study indicate that 
if the first episode of AF is reverted with oral amio-
darone therapy or ECV, and SR is maintained for at 
least 3 months, with amiodarone, more than 50% 
of these patients will not experience AF relapses 
during the subsequent 15 months. Furthermore, 
this approach significantly reduces drug-related 
side effects. Patients who regain normal SR with 
amiodarone show a high rate of persistent long-
-term SR when the drug is administered for long 
periods.
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